Tests a magnetic brain stimulation device with cognitive training for mild Alzheimer's
Tests a non-invasive magnetic and cognitive training device in people with mild Alzheimer's.
Key facts
- Who runs it
- Advanced Technology & Communications
- Where
- Busan, Daegu, Daejeon, Gwangju, Gwangmyeong, Gyeonggi-do, Incheon, Jeonju, and Seoul, South KoreaSee the 11 sites
- Trial code
- Registry title
- Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 15 May 2023
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ATNC MDD-V1 (Real TMS + Real Cog)
- ATNC MDD-V1 (Sham TMS + Real Cog)
- ATNC BN-V1
- ATNC BN-V2
- Record updated
- 23 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 60-85 with mild Alzheimer's disease, confirmed by an amyloid PET-CT scan, who already take an acetylcholinesterase inhibitor.
- Age
- 60 to 85 years
- Sex
- All sexes
- Disease stage
- Mild Alzheimer's disease (NIA-AA 2011), confirmed by amyloid PET-CT. MMSE score 21 to 26. CDR 1 or GDS 3.
- Earlier treatment
- Must have started an acetylcholinesterase inhibitor at least 2 months before joining, with no dose change during the trial. No TMS treatment in the last 2 years. No other clinical trial in the last 3 months.
- Biomarker or test result
- Amyloid PET-CT confirming that the dementia is due to Alzheimer's disease.
Main reasons for not taking part
- Other brain diseases that may affect thinking, or other types of dementia
- History of epileptic seizures or epilepsy
- Metal implants in the head, cardiac pacemaker, implanted medication pump or intracardiac lines
- Significant heart disease, or severe kidney or liver problems
- Cannot have an MRI or an amyloid PET-CT scan
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period
- Male or female age 60-85 years
- Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis
- A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT
- MMSE score 21 to 26
- CDR 1 or GDS 3; ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed
- A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination
- A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver
- Patients who agreed to participate in all 24-week clinical trials
- Patients with normal ability to see and hear letters
- Patients who speak Korean as their mother tongue
Who cannot take part
- Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination
- Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants
- Implanted medication pumps
- Patients who are currently taking medications that lower the convulsive seizure threshold
- Patients who participated in other clinical trials 3 months before participating in this clinical trial; ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study
- Patients who need to take medications suggested in concomitantly contraindicated drugs
- Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected
- History of Epileptic Seizures or Epilepsy
- Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening
- Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder
- Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia
- Cardiac pacemakers
- Significant heart disease
- Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment
- Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial
- Patients with a history of malignant tumors within the last 5 years; Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.)
- Intracardiac lines
- Contraindication for performing MRI scanning
- Contraindication for performing amyloid PET-CT scanning
- Patients who do not consent to TMS treatment and participation in this clinical trial
- Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons; ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 85 years old?
Where in South Korea
- Dong-A University HospitalBusan, South KoreaContact: AT&CTaking people
- Yeungnam University Medical CenterDaegu, South KoreaContact: AT&CTaking people
- Chungnam National University HospitalDaejeon, South KoreaContact: AT&CTaking people
- Chonnam National University HopitalGwangju, South KoreaContact: AT&CTaking people
- Chung-Ang University Gwangmyeong HospitalGwangmyeong, South KoreaContact: AT&CTaking people
- Inje University Ilsan Paik HospitalGyeonggi-do, South KoreaContact: AT&CTaking people
- National Health Insurance Service Ilsan HospitalGyeonggi-do, South KoreaContact: AT&CTaking people
- Catholic university of Korea Incheon St. Mary's HospitalIncheon, South KoreaContact: AT&CTaking people
- jeonbuk National University HospitalJeonju, South KoreaContact: AT&CTaking people
- Konkuk University Medical CenterSeoul, South KoreaContact: AT&CTaking people
- Korea University Anam HospitalSeoul, South KoreaContact: AT&CTaking people
About the trial
What the trial wants to find out
The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.
The 2 groups in the trial
- ATNC MDD-V1Existing treatment, for comparison
ATNC MDD-V1 treatment, synchronized TMS and cognitive training stimulation
Treatment: ATNC MDD-V1 (Real TMS + Real Cog), ATNC BN-V1, and ATNC BN-V2
- Sham TMS + Real CogSham treatment, for comparison
The Control arm subjects will receive daily treatments five days a week for 6 consecutive weeks of Sham treatment of TMS and real cognitive training which is similar to the real treatment in visit frequency and procedure.
Treatment: ATNC MDD-V1 (Sham TMS + Real Cog), ATNC BN-V1, and ATNC BN-V2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study
- Plain-language title
- Tests a magnetic brain stimulation device with cognitive training for mild Alzheimer'sGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06088121, who can take part
- Record updated
- 23 April 2026